Current treatment guidelines recommend a initiation of Highly Active Anti-Retroviral Therapy (“HAART”) when T cell count <350 cells/mm3 in order to minimize the risk of therapeutic failure because of drug resistance or non-compliance driven by undesirable side effects. Current estimates suggest that 30% to 50% of people infected with HIV eventually develop resistance to one or more HAART drug combinations.  Unfortunately, the sustained immune activation initiated by the infection and chronic viral replication slowly deteriorates the immune system, laying the foundation for AIDS well before corrective therapy can begin.  Therefore, there is a chronic need for new drugs and new therapeutic approaches that can be used earlier after infection.

Antiviral Immune Modulating (AIM) therapy

To meet this challenge, the Company’s is developing Antiviral Immune Modulating or AIM Therapy. This approach utilizes select proprietary combinations of Antivirals and Immune Modulators that provide a synergistic impact to viral entry and replication. These AIM Therapy combinations will allow for:

1. Reduced Side Effects - delivery of antivirals at doses lower than currently used to minimize the adverse side effects of these drugs that, in part, drives non-compliance,
   
   
2. More Effective Therapy - “cooling” the overheated activated state of the immune system that provides an optimal environment for viral replication and exacerbates the disease course,
   
   
3. Constricting viral reservoirs – reducing the number of quiescent immune cells infected with latent forms of virus that are the foundation of the chronic infection,
   
   
4. Earlier Treatment - slowing or preventing the emergence of drug-resistant viruses that drives treatment failure thus enabling initiation of therapy earlier after infection,
   
   
5. Combating Drug Resistance - restoring susceptibility to antivirals in patients where drug resistance limits treatment options.